TABLE 1

Clinical characteristics of subjects at study entry

Sex (M/F)Anti-GAD65 auto-antibody positive (%)Anti–IA-2 auto-antibody positive (%)Age (years)Weeks after diagnosisInsulin dose (units/kg)BMI (kg/m2)Basal C-peptide (pmol/ml)Peak C-peptide (pmol/ml)
All patients with type 1 diabetes (n = 41)25/16856914.8 ± 0.93 (7–30)5.42 ± .29 (2–10)0.46 ± 0.04 (0–1.06)19.7 ± 0.56 (14.4–28.3)0.23 ± 0.03 (0.03–1.14)0.60 ± 0.04 (0.15–0.30)
Patients with type 1 diabetes followed for 24 months (n = 20)9/11856515.3 ± 1.35 (8–30)6.65 ± 0.37 (4–10)0.44 ± 0.05 (0–0.83)19.9 ± 0.72 (14.8–25.5)0.25 ± 0.05 (0.09–1.14)0.61 ± 0.06 (0.26–1.30)
Nondiabetic control subjects (n = 38)16/22NDND21.8 ± 0.83 (13–30.6)23.4 ± 0.46 (17.1–28.9)0.39 ± 0.02 (0.12–0.97)1.81 ± 1.11 (0.98–4.64)
  • Data are means ± SE (range). ND, not determined.